ALKS Q3 2017 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$217M+20.6% YoY

Gross Profit

$181M83.4% margin

Operating Income

-$38M-17.6% margin

Net Income

-$36M-16.7% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

-0.7%

Cash Flow

Operating Cash Flow

$19M

Free Cash Flow

$7M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$561M

Stockholders' Equity

$1.2B

Cash & Equivalents

$165M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$217M	$180M	+20.6%
Gross Profit	$181M	$145M	+25.2%
Operating Income	-$38M	-$61M	+37.3%
Net Income	-$36M	-$63M	+42.1%